Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib in Huntington's Disease
NCT03764215Phase 1Unknown
- Sponsor
- Georgetown University
- Start
- Nov 2018
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of nilotinib in Huntington disease (HD) (2 arms), sponsored by Georgetown University. Primary endpoints: Number of participants experiencing any Adverse events and Serious Adverse Events at 3 months, CSF levels of biomarkers linked to Disease symptoms Chorea and behavioral symptoms at 3 months and 1 more. Status: unknown.
02
Drugs
nilotinib
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on NCT03764215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03764215.